Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02734602 · ClinicalTrials.gov registry record · NA
Imaging SV2A in Mood Disorders
A NA study of Major Depressive Disorder and Post Traumatic Stress Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 130
- Enrollment target
- 1
- Study location
NCT02734602 is a NA study of Major Depressive Disorder and Post Traumatic Stress Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 130 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02734602, a NA study of Major Depressive Disorder and Post Traumatic Stress Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects. To our knowledge, this is the first human study to examine SV2A in vivo in MDD and PTSD and to use the first known drug (ketamine) that rapidly reverses synaptic loss to determine whether ketamine administration could restore some of the structural changes associated with depression and PTSD. After a screening process to determine eligibility, all subjects will participate in an MRI, and 2-3 PET scans with the administration of ketamine for one of the scans. Cognitive testing and a stress test may also be done on scan days.
Conditions Studied
Interventions
- DRUG Ketamine
Study Locations (1)
Connecticut
- PET Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2016-04 |
| Est. Completion | 2027-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02734602
The ClinicalTrials.gov registry entry for NCT02734602 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (65% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Ketamine is the first listed.
NCT02734602 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02734602 about?
NCT02734602 is a clinical study titled "Imaging SV2A in Mood Disorders". This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects. To our knowledge, this is the first human study to examine SV2A in vivo in MDD and PTSD and to...
What is the current status of trial NCT02734602?
This trial is currently recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2016-04. Estimated completion is 2027-03.
What conditions does trial NCT02734602 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT02734602?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT02734602?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02734602 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
-
Positive Processes and Transition to Health (PATH)
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
RECRUITING · NA
Explore more on PlainTrial
Major Depressive Disorder
All registered trials for this condition
Post Traumatic Stress Disorder
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.